Bendamustine more effec.than chlorambucil for adv. Chronic Lymphocytic Leukemia (CLL)
Posted 08-21-2009 at 06:20 PM by admin
HemOnc today
August 20, 2009
Bendamustine treatment demonstrated better overall response rate and PFS than chlorambucil treatment in previously untreated patients with advanced CLL.
Researchers conducted a phase-3 multicenter study and randomly assigned 319 patients IV bendamustine (Treanda, Cephalon) 100 mg/m2 per day on days one to two, or chlorambucil (Leukeran, Smithkline Beecham) 0.8 mg/kg orally on days one and 15. Every four weeks, treatment cycles were repeated for a maximum of six cycles.
Overall, 68% of 162 patients in the bendamustine group and 31% of 157 patients in the chlorambucil group had complete or partial response (P<.0001).
More patients treated with bendamustine (31%) had complete response vs. patients treated with chlorambucil (2%). Additionally, 11% of patients in the bendamustine group had nodular partial response compared with 3% of patients in the chlorambucil group.
Among patients with Binet stage C disease, 20% treated with bendamustine demonstrated complete response, whereas no patients treated with chlorambucil did.
The bendamustine group demonstrated a higher median PFS rate (21.6 months) compared with the chlorambucil group (8.3 months; P<.0001); this difference was observed in patients with both Binet stage B and C disease.
The median duration of response was 21.8 months in patients treated with bendamustine and only eight months in patients treated with chlorambucil.
Grade-3 or -4 severe infections were noted in 8% of patients in the bendamustine group and in 3% of patients in the chlorambucil group.
Knauf WU. J Clin Oncol. 2009;doi:10.1200/JCO.2008.20.8389.
Copyright © 2009 HemOnc Today. All Rights Reserved.
August 20, 2009
Bendamustine treatment demonstrated better overall response rate and PFS than chlorambucil treatment in previously untreated patients with advanced CLL.
Researchers conducted a phase-3 multicenter study and randomly assigned 319 patients IV bendamustine (Treanda, Cephalon) 100 mg/m2 per day on days one to two, or chlorambucil (Leukeran, Smithkline Beecham) 0.8 mg/kg orally on days one and 15. Every four weeks, treatment cycles were repeated for a maximum of six cycles.
Overall, 68% of 162 patients in the bendamustine group and 31% of 157 patients in the chlorambucil group had complete or partial response (P<.0001).
More patients treated with bendamustine (31%) had complete response vs. patients treated with chlorambucil (2%). Additionally, 11% of patients in the bendamustine group had nodular partial response compared with 3% of patients in the chlorambucil group.
Among patients with Binet stage C disease, 20% treated with bendamustine demonstrated complete response, whereas no patients treated with chlorambucil did.
The bendamustine group demonstrated a higher median PFS rate (21.6 months) compared with the chlorambucil group (8.3 months; P<.0001); this difference was observed in patients with both Binet stage B and C disease.
The median duration of response was 21.8 months in patients treated with bendamustine and only eight months in patients treated with chlorambucil.
Grade-3 or -4 severe infections were noted in 8% of patients in the bendamustine group and in 3% of patients in the chlorambucil group.
Knauf WU. J Clin Oncol. 2009;doi:10.1200/JCO.2008.20.8389.
Copyright © 2009 HemOnc Today. All Rights Reserved.
Total Comments 0
Comments
Recent Blog Entries by admin
- Research and Markets: Market of Paclitaxel Injection in China (08-20-2010)
- Relief for cancer patients may be 2,000 years old (08-20-2010)
- Melanoma Research Alliance Announces $5.2 Million in New Grants (08-20-2010)
- Melanoma Research Alliance Announces $5.2 Million in New Grants to Support Six Innova (08-20-2010)
- Breast cancer survivors don't need to be afraid of air travel: U of A study (08-20-2010)
